[Animal studies on ribostamycin (author's transl)].
Nephrotoxicity, pharmacokinetics, and therapeutic efficacy of ribostamycin were evaluated in rats. Measures of nephrotoxicity were urinary excretion of tubular cells and malate dehydrogenase. The i.v. injections of ribostamycin lead to the same tubular cell excretion values as the i.m. injections. Parallel administration of D-glucaro-delta-lactam reduced the nephrotoxic effect of ribostamycin significantly. The lowest dose which leads to a significantly increased loss of tubular cells was 20 mg/kg/d and was distinctly above that of gentamicin, indicating a lower nephrotoxicity. This corresponded to lower renal ribostamycin concentrations after a single dose administration as well as after 9 times repeated dosing. In chemotherapy of the acute pyelonephritis of the rat ribostamycin was inferior to gentamicin at dosages of 2.5 or 5 mg/kg.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D005937:Glucaric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006207:Half-Life; D007668:Kidney / Q000187:drug effects; D007769:Lactams / Q000627:therapeutic use; D011704:Pyelonephritis / Q000188:drug therapy*; D051381:Rats; D012271:Ribostamycin / Q000378:metabolism / Q000627:therapeutic use*; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D007769:Lactams; D012271:Ribostamycin; C001845:D-glucaro-delta-lactam; D005937:Glucaric Acid
Tierexperimentelle Studien mit Ribostamycin.